BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25241128)

  • 21. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
    Park H; Kim S; Kim YE; Lim SJ
    ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
    Henkes LM; Haus P; Jäger F; Ludwig J; Meyer-Almes FJ
    Bioorg Med Chem; 2012 Jan; 20(2):985-95. PubMed ID: 22182579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
    Hassanzadeh M; Bagherzadeh K; Amanlou M
    J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents.
    Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes.
    Griffith DM; Szocs B; Keogh T; Suponitsky KY; Farkas E; Buglyó P; Marmion CJ
    J Inorg Biochem; 2011 Jun; 105(6):763-9. PubMed ID: 21496451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
    Belvedere S; Witter DJ; Yan J; Secrist JP; Richon V; Miller TA
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3969-71. PubMed ID: 17507219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
    Oger F; Lecorgne A; Sala E; Nardese V; Demay F; Chevance S; Desravines DC; Aleksandrova N; Le Guével R; Lorenzi S; Beccari AR; Barath P; Hart DJ; Bondon A; Carettoni D; Simonneaux G; Salbert G
    J Med Chem; 2010 Mar; 53(5):1937-50. PubMed ID: 20143840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
    Wong JC; Hong R; Schreiber SL
    J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
    Zuo M; Zheng YW; Lu SM; Li Y; Zhang SQ
    Bioorg Med Chem; 2012 Jul; 20(14):4405-12. PubMed ID: 22698782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
    Choi E; Lee C; Cho M; Seo JJ; Yang JS; Oh SJ; Lee K; Park SK; Kim HM; Kwon HJ; Han G
    J Med Chem; 2012 Dec; 55(23):10766-70. PubMed ID: 23163332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
    Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
    Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
    Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
    Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.
    Singh RK; Lall N; Leedahl TS; McGillivray A; Mandal T; Haldar M; Mallik S; Cook G; Srivastava DK
    Biochemistry; 2013 Nov; 52(45):8139-49. PubMed ID: 24079912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.